This is Part II of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Administering medication transdermally offers several advantages over other methods of drug delivery.
BioSante Pharmaceuticals may be known for its sexual health products such as LibiGel, but the Illinois-based company is also developing a novel immunotherapy vaccine to treat cancer.
The company’s main products are LibiGel, a testosterone gel for women, and Elestrin, which is approved to treat menopause-related hot flashes.
Stephen Simes, President and CEO of BioSante Pharmaceuticals, speaks about his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Copyright © 2025 | WordPress Theme by MH Themes